Introduction

Top Abstract Introduction Results Discussion References

Stampidine is a novel aryl phosphate derivative of stavudine, which inhibits the replication of human immunodeficiency virus (HIV¹)-1 in human peripheral blood mononuclear cells at nanomolar concentrations (Venkatachalam et al., 1998; Vig et al., 1998; Uckun and Vig, 2000).

Stampidine is substantially more potent than stavudine against primary clinical HIV-1 isolates. Importantly, stampidine was active against phenotypically and/or genotypically nucleoside reverse transcriptase inhibitor (NRTI)-resistant HIV with low nanomolar to subnanomolar IC₅₀ values (Uckun et al., 2002c). Similarly, stampidine inhibited the replication of laboratory HIV-1 strains and primary clinical HIV-1 isolates with non-nucleoside reverse transcriptase inhibitors binding site mutations (K103N, V106N, Y179I, Y181C, and Y188L) and/or a phenotypically non-nucleoside reverse transcriptase inhibitor-resistant profile with low nanomolar to subnanomolar IC₅₀ values. Notably, stampidine exhibited dose-dependent and potent in vivo anti-HIV activity in Hu-PBL-SCID mice against a genotypically and phenotypically NRTI-resistant clinical HIV-1 isolate at nontoxic dose levels (Uckun et al., 2002b).

We recently studied the in vivo metabolism of this new anti-HIV agent in rodent species (Chen et al., 2001; Uckun et al., 2002a,b). In mice and rats, stampidine was found to form two active metabolites, namely, alaninyl-STV-monophosphate (Ala-STV-MP) and STV (Chen et al., 2001; Uckun et al., 2002b,c). The goal of the present study was to extend our studies to large animal species. Herein, we report the pharmacokinetics and metabolism of stampidine in dogs and cats. Also reported is the identification of a novel in vivo metabolite of stampidine and its pharmacokinetics in mice, dogs, and cats.

Materials and Methods

Anti-HIV Drugs and Chemicals. HPLC-grade reagents and deionized, distilled water obtained from Milli-Q purification system (Millipore, Medford, MA) were used in this study. Acetonitrile was purchased from Burdick and Jackson (Allied Signal Inc., Muskegon, MI). Hydrochloric acid was purchased from Fisher Scientific (Fair Lawn, NJ). Ammonium phosphate, adenosine 3'-phosphate 5'-phosphosulfate (PAPS), porcine liver esterase (catalog no. E2884), thymine, and phosphoric acid were purchased from Sigma-Aldrich (St. Louis, MO). Microcrystalline Cellulose NF (Avicel PH 101) was obtained from FMC Bioproducts (Newark, DE). Magnesium stearate NF was obtained from Spectrum Chemicals (Gardena, CA), and hard gelatin capsules sizes 4 and 00 were obtained from Capsugel Corporation (Greenwood, SC). The synthetic procedures for the preparation of stampidine and STV-5'[para-bromophenyl methoxyalanininyl phosphate] have been described in detail (Fig. 1) previously (Venkatachalam et al., 1998; Vig et al., 1998; Uckun and Vig, 2000).

View larger version (16K): [in this window] [in a new window]   Fig. 1.   Proposed in vivo metabolism of stampidine. A new metabolite, p-bromophenyl sulfate, was identified. The compounds in parenthesis are the intermediate compounds that are not detected in animals.

Synthesis and Characterization of Newly Proposed Assigned Metabolites. All chemicals were purchased from Aldrich Chemical Co. (Milwaukee, WI) and used without further purification. All reactions were carried out under nitrogen. Melting points are not corrected; UV spectra were determined with an ultraviolet spectrophotometer; and ¹H NMR, ¹³C NMR, and ³¹P NMR spectra were determined on the Oxford 300-MHz spectrometer (Varian, Palo Alto, CA) using an automated broadband probe. Chemical shifts are expressed in ppm downfield from an internal reference of tetramethylsilane. The following compounds were synthesized and characterized as potential metabolites of stampidine:

p-Bromophenyl Phosphate. p-Bromophenyl phosphate was synthesized as follows: 54.0 µl (3.0 mmol) of H₂O was added to a solution of 200 mg (0.69 mmol) p-bromophenyl phosphorodichloridate in anhydrous toluene at 0°C. The solution was stirred at room temperature for 3 h then at 50°C for 1 h. The solvent was removed under reduced pressure; a white crystallization of 175 mg (100%) was obtained. ¹H NMR (CD₃OD)  7.12-7.15 (d, 2H, J = 9.0 Hz, Ar-2,6), 7.47-7.50 (d, 2H, J = 9.0 Hz, Ar-3,5); ¹³C NMR (CD₃OD)  117.1, 122.1, 132.4, 150.8. ³¹P NMR  4.87; UV _max = 222 nm; MS(EI) 251/253 (100%).

2',3'-Didehydro-3'-deoxythymidine 5'-(Methoxyalaninyl Phosphate) Triethylammonium Salt. The synthesis of this compound was started with equimolar phosphorylation of methoxyalanine, followed by equimolar substitution with STV, and subsequent hydrolysis with triethylammonium bicarbonate buffer (Scheme 1). To a solution of L-alanine methyl ester hydrochloride (1.41 g, 10 mmol) and phosphorus oxychloride (0.94 ml, 10 mmol) in anhydrous dichloromethane (50 ml) at 78°C was added a solution of triethylamine (2.80 ml, 20 mmol) in anhydrous dichloromethane (50 ml) dropwise while stirring. The reaction mixture was allowed to warm up to room temperature, followed by stirring overnight. The reaction mixture was filtered and rinsed with anhydrous ether under suction. The filtrate was concentrated under reduced pressure to yield methoxyalaninyl phosphorodichloridate (2.17 g, 99% yield) as a colorless oil. STV (0.22 g, 1 mmol), methoxyalaninyl phosphorodichloridate (0.59 ml, 3 mmol), and triethylamine (0.56 ml, 4 mmol) were dissolved in anhydrous tetrahydrofuran (10 ml) and stirred overnight. To this solution, 10 ml of triethylammonium bicarbonate buffer was added at 0°C with stirring. The mixture was concentrated and purified with flash chromatography (CHCl₃/MeOH = 1:1) and preparative TLC (CHCl₃/MeOH/H₂O = 10/5/1), yielding 4.0 mg of the target compound. ¹H NMR (CD₃OD)  1.25 to 1.33 (m, 12H, Ala-CH₃ and CH₃CH₂), 1.94 (s, 3H, 5-CH₃), 3.31 (q, 6H, CH₃CH₂), 3.67 (s, 3H, OCH₃), 3.70 (s, 2H, 5'-H), 3.78 to 3.87 (m, 1H, N-CH), 3.97 to 4.00 (m, 2H), 4.94 (s, 1H, 4'-H), 5.86 (d, 1H, J = 6.0Hz, 1'-H), 6.42 (d, 1H, J = 6.0 Hz, 2'-H), 6.96 (m, 1H, 3'-H), 7.70 (s, 1H, 6-H); ¹³C NMR (CD₃OD)  11.6, 20.5, 47.1 to 48.8, 50.3, 51.3, 65.2, 86.2, 89.7, 110.9, 125.8, 134.6, 137.5, 152.1, 166.1, 176.2; ³¹P NMR  6.23; UV _max = 266 nm; MS(EI) 196 (40%), 267 (92%), 388 (100%).

View larger version (6K): [in this window] [in a new window]   Scheme 1.   Synthesis of 2',3'-Didehydro-3'-deoxythymidine 5'-(methoxyalaninyl phosphate) triethylammonium salt.

5'-(4-Bromophenylphospho)-2',3'-didehydro-3'-deoxythymidine Triethylammonium Salt. To a solution of 250 mg (0.87 mmol) of p-bromophenyl phosphorodichloridate in anhydrous pyridine at 0°C, 3.0 ml of 195 mg (0.87 mmol) STV in anhydrous pyridine was added over 20 min. The resulting solution was stirred for 1 h and then warmed to room temperature. After stirring at room temperature for 6 h, and then at 50°C for 2 h, the solvent was removed under reduced pressure. Acetonitrile (3.0 ml) and 1.0 M triethylammonium bicarbonate buffer solution (3.0 ml) were added, and the solution was stirred for 2 h. Finally, the solvent was removed and the residue was purified through flash chromatography over silica gel (CHCl₃/MeOH = 1:1) to obtain the target compound as a white solid (196 mg, 50%). An analytical sample was obtained by preparative TLC (CHCl₃/MeOH/H₂O = 10/5/1). ¹H NMR (CD₃OD)  1.31 (t, 9H, CH₃CH₂), 1.75 (s, 3H, 5-CH₃), 3.20 (q, 6H, CH₃CH₂), 4.14 to 4.16 (m, 2H, 5'-H), 4.99 (s, 1H, 4'-H), 5.88 (d, 1H, J = 8.7Hz, 1'-H), 6.39 (d, 1H, J = 8.7Hz, 2'-H), 6.96 (m, 1H, 3'-H), 7.09 (d, 2H, J = 8.7 Hz, Ar-2, 6), 7.33 (d, 2H, J = 8.7Hz, Ar-3, 5), 7.57 (s, 1H, 6-H); ¹³C NMR (CD₃OD)  8.21, 11.4, 47.1 to 48.8, 66.5, 85.8, 89.7, 110.7, 115.7, 122.3, 126.3, 131.9, 134.1, 138.0, 151.6, 152.3, 165.1. ³¹P NMR  4.54. UV _max = 260 nm; MS(EI) 331/333 (35%), 457/459 (100%).

N-(Hydroxy-4-bromophenoxyphosphinyl)-L-analine-methyl Ester Triethylammonium Salt. A solution of alanine-methyl ester hydrochloride (97 mg, 0.69 mmol) in anhydrous pyridine (2.0 ml) was added to a solution of p-bromophenyl phosphorodichloridate (200 mg, 0.69 mmol) in anhydrous pyridine at 0°C, over 20 min. After stirring at room temperature for 8 h and at 50°C for 2 h, the solvent was removed under reduced pressure. The residue was treated with acetonitrile (3.0 ml) and 1.0 M triethylammonium bicarbonate buffer solution (2.0 ml) and stirred for 2 h. The solvent was removed in vacuo and the residue was purified by flash chromatography on silica gel (CHCl₃/MeOH = 1:1) to obtain a white solid (45 mg, 62%). An analytical sample was obtained through preparative TLC (CHCl₃/MeOH/H₂O = 10/5/1). ¹H NMR (CD₃OD)  1.28 (t, 9H, CH₃CH₂), 1.32 (s, 3H, Ala-CH₃), 3.18 (q, 6H, CH₃CH₂), 3.61 (s, 3H, OCH₃), 3.88 (m, 1H, N-CH), 7.11 (d, 2H, J = 8.4Hz, Ar-2,6), 7.37 (d, 2H, J = 8.4 Hz, Ar-3,5); ¹³C NMR (CD₃OD)  8.2, 20.4, 46.8 to 48.8, 50.7, 51.3, 114.8, 122.3, 131.8, 152.9, 175.7; ³¹P NMR  1.87; UV _max = 220 nm; MS(EI) 336/338 (100%).

4-Bromophenyl Sulfate. To a mixture of p-bromophenol (1.00 g, 5.78 mmol) and sulfur trioxide pyridine complex (0.93 g, 5.84 mmol), anhydrous pyridine (12 ml) was added. The resulting suspension was stirred for 4 h and then at 50°C for 4 h. After removal of all solvent under reduced pressure, H₂O (50 ml) was added and extracted using chloroform three times. The solution was concentrated in vacuo and the residue was purified by flash chromatography on silica gel (CHCl₃/MeOH = 3:1) to obtain white solid (o.935 g, 64%). ¹H NMR (CD₃OD)  7.19-7.22 (d, 2H, J = 9.0Hz, Ar-2, 6), 7.43 to 7.46 (d, 2H, J = 9.0Hz, Ar-3, 5); ¹³C NMR (CD₃OD),  117.2, 123.2, 131.9, 152.1; UV _max = 254 nm; MS(EI) 251/253 (100%), 171/173 (20%).

Identification of a New in Vivo Stampidine Metabolite.

Sample Pretreatment In brief, each plasma sample (200 µl) was mixed 1:4 with acetone (800 µl) and vortexed for at least 30 s. After centrifugation, the supernatant was transferred into a clean tube and was dried under nitrogen. A 50-µl solution of 50% methanol in 200 mM HCl was used to reconstitute the extraction residue, and 40 µl was injected into the HPLC.

HPLC conditions. The HPLC system used for these studies was a Hewlett Packard (Palo Alto, CA) series 1100 instrument equipped with a quaternary pump, an autosampler, an automatic electronic degasser, an automatic thermostatic column compartment, a diode array detector, and a computer with Chemstation software for data analysis (Chen et al., 1999a,c,e). The analytical column used was a Zorbax SB-Phenyl (5 µm; Agilent Technologies, Kenner, LA) column attached to a guard column (Agilent Technologies). The column was equilibrated before data collection. The linear gradient mobile phase (flow rate = 1.0 ml/min) used was 100% A/0% B at 0 min, 88% A/12% B at 20 min, and 8% A/92% B at 30 min (A, 10 mM ammonium phosphate buffer, pH 3.7; B, acetonitrile). The detection wavelength was 268 nm and the peak width, response time, and slit were set at >0.03 min, 0.5 s and 4 nm, respectively.

Mass spectrometry. Mass spectrometry was carried out using atmospheric pressure ionization-electrospray and a high-energy-dynode electron multiplier that are connected to the liquid chromatography system (Agilent Technologies) (Chen et al., 1999f; Chen and Uckun, 2000). Liquid chromatographic conditions were described as above except that flow rate was 0.5 ml/min. High-purity nitrogen was provided by Nitrogen Generator (Agilent Technologies). The conditions for mass spectrometry were set at a fragmentor voltage of 75 V, drying gas flow of 10 l/min, nebulizer pressure of 25 psig, and drying gas temperature of 350°C. Both positive and negative ion monitoring with scanning mode were performed at a capillary voltage of 3500 V.

Animals. Female BALB/c mice (6-8 weeks old) (Taconic Farms, Germantown, NY) and female CD-1 mice (6-8 week old) (Charles River Laboratories, Inc., Wilmington, MA) were housed in an USDA-accredited animal care facility under standard environmental conditions (12-h light/dark photoperiod, 22 ± 1°C, 60 ± 10% relative humidity). All rodents were housed in microisolator cages (Lab Products, Inc., Maywood, NJ) containing autoclaved bedding. Mice were allowed free access to autoclaved pellet food and tap water throughout the study.

Pharmacokinetic Studies in Animals. A solution of stampidine dissolved in dimethyl sulfoxide was administered i.v. to mice via tail vein injection at a dose of 100 mg/kg. Two to five mice per strain per time point were used for pharmacokinetic studies. Blood samples (~500 µl) were obtained from the ocular venous plexus by retro-orbital venipuncture at 0, 2, 5, 10, 15, 30, 45, 60, 120, 240, and 360 min after i.v. injection. To determine the pharmacokinetics of stampidine after its oral administration to mice, 12-h fasted mice were given a bolus dose of 100-mg/kg stampidine via gavage using a stainless steel ball-tipped feeding needle. Blood sampling time points were 0, 2, 5, 10, 15, 30, 45, 60, 120, 240, and 360 min after the gavage.

Incubation of Stampidine with Liver Microsomes and Cytosol Preparations. The incubation mixtures of stampidine with either human or nonhuman liver microsomes contained the following components (Uckun et al., 2002d) at the indicated final concentrations (200 µl): 1× PBS, 1 mg/ml microsomes, 10 nM glucose 6-phosphate, 2 units/ml glucose-6-phosphate dehydrogenase, and 5 mM MgCl₂. The mixtures were preincubated at 37°C for 5 min. The metabolism reaction was initiated by the addition of stampidine. After incubation for 10 min, the reaction was stopped by addition of 800 µl of acetone and the suspension was thoroughly mixed using a vortex device. The mixtures were extracted and separated through the HPLC conditions as described above.

	Results

Top Abstract Introduction Results Discussion References

Identification of a New Stampidine Metabolite in Plasma. We have previously reported the identification of ala-STV-MP and STV as two of the three major in vivo metabolites of stampidine (Chen et al., 2001). However, the identity of the third metabolite eluting at a retention time of 26.8 min has remained elusive (Chen et al., 2001). Online liquid chromatography-MS analysis of murine plasma samples revealed that this candidate metabolite has an m/z of the same intensity of molecular ion at 250.9/252.9 and fragment ion at 170.9/172.9. These data prompted the hypothesis that the candidate metabolite may be bromophenyl phosphate. However, the synthesized p-bromophenyl phosphate had a retention time of 11.6 min, which is significantly shorter than the observed retention time of the candidate metabolite (26.8 min) (Fig. 3).

View larger version (22K): [in this window] [in a new window]   Fig. 2.   Mass spectrum for new metabolite. Computer simulation for isotope distribution for both p-bromophenyl sulfate (A1) and p-bromophenyl phosphate (B1); the mass spectrum for the metabolite isolated from mice treated with stampidine (A2) and for the synthetic authentic p-bromophenyl phosphate (B2).

View larger version (29K): [in this window] [in a new window]   Fig. 3.   HPLC chromatograms for possible hydrolysis metabolite. A, proposed hydrolysis metabolites. B, HPLC chromatograms for separation of the proposed metabolites. C, HPLC chromatogram from a BALB/c mice at 15 min post-i.v. injection (100 mg/kg stampidine).

View larger version (14K): [in this window] [in a new window]   Fig. 4.   Metabolite pharmacokinetics of p-bromophenyl sulfate in mice. Murine plasma p-bromophenyl sulfate concentrations as a function of time after intravenous () and oral administration () of 100 mg/kg stampidine. Depicted is data from two BALB/c + four CD-1 mice after intravenous () and four BALB/c + four CD-1 mice () for each time point.

Pharmacokinetics and Metabolism of Stampidine in Cats and Dogs. We next set out to evaluate the pharmacokinetics and metabolism of stampidine (dose level 100 mg/kg) in four healthy beagle dogs and three chronically feline immunodeficiency virus-infected domestic cats administered orally after an overnight fasting. In dogs, the estimated average plasma C_max and AUC values were 15.4 ± 6.1 µM and 23.1 ± 5.4 µM · h, respectively (Table 2). C_max value was achieved with a T_max of 112.8 ± 46.2 min. The average elimination half-life (t_1/2) was 108.6 ± 28.8 min. In cats, the estimated average plasma C_max and AUC values were 7.5 ± 1.6 µM and 7.1 ± 1.1 µM · h, respectively (Table 2). C_max was achieved with a T_max of 106.2 ± 57.0 min. The average t_1/2 was 50.5 ± 15.8 min.

View larger version (16K): [in this window] [in a new window]   Fig. 5.   Metabolite pharmacokinetics in dogs and cats. Plasma Ala-STV-MP (A), STV (B), and p-bromophenyl sulfate (C) concentrations as a function of time after oral administration of 100 mg/kg stampidine to the both dogs (N = 4) and cats (N = 3).

Involvement of Liver Enzymes in the Metabolism of Stampidine. The identification of p-Br-Ph-S as the third major in vivo metabolite of stampidine prompted the hypothesis that stampidine metabolism results in generation of p-bromophenol that is then converted to p-Br-Ph-S via sulfonation. To study the role of sulfonation reactions in the metabolism of stampidine, we first tested whether sulfonation of p-bromophenol can be enzymatically catalyzed. No p-Br-Ph-S was formed in a reaction medium containing human liver cytosol without PAPS as a sulfonation donor, or in a reaction medium containing PAPS but no cytosol. In contrast, in a complete reaction medium containing 100 µM p-bromophenol, the formation rate of p-Br-Ph-S (mean ± S.E.M.) was 281.2 ± 14.3 pmol/min/mg cytosolic protein.

View larger version (25K): [in this window] [in a new window]   Fig. 6.   HPLC profiles for stampidine metabolism in human liver cytosol. Incubation of stampidine with sulfonation medium in the presence of PAPS but no cytosol (A), cytosol but no PAPS (B), and cytosol and PAPS (C).

	Discussion

Top Abstract Introduction Results Discussion References

Our results indicate that stampidine can be quickly biotransformed to two active phase I metabolites, Ala-STV-MP and STV, and a phase II metabolite, p-Br-Ph-S (Fig. 1). Ala-STV-MP was considered as an intra- and/or extracellular depot form of STV and/or STV-MP (Balzarini et al., 1996a,b; Naesens et al., 1998), whereas STV is a clinically used anti-HIV drug (Lea and Faulds, 1996). The formation of the major metabolite Ala-STV-MP is consistent between the in vitro (Venkatachalam et al., 1998) and in vivo systems (Vig et al., 1998; Chen et al., 2001); however, the formation of STV was found in plasma but not in cells.

In this report, we identified a significant amount of p-Br-Ph-S in animals treated with stampidine and trace amounts of p-bromophenol that could not be quantitated. p-Bromophenol has a very low toxicity, because the oral LD₅₀ value for p-bromophenol was over 500 mg/kg (Sigma-Aldrich MSDS for 4-bromophenol). As a metabolite for bromobenzene, p-bromophenol has been shown not to contribute to the toxicity of bromobenzene (Monks et al., 1982; Dankovic and Billings, 1985). Further metabolism of p-bromophenol to form a glutathione conjugate was also found to be nontoxic in vivo (Monks et al., 1984). The sulfonation pathway generally results in detoxification and facilitates the elimination of the metabolites (Negishi et al., 2001). Therefore, p-Br-Ph-S should have little or no toxicity. In preliminary studies, p-Br-Ph-S was nontoxic to mice after i.p. administration at dose levels ranging from 10 to 300 mg/kg (data not shown).

Two in vitro metabolism pathways for the formation of Ala-STV-MP and STV have been proposed for stampidine (Venkatachalam et al., 1998) and other masked alaninyl STV-MP derivatives (Balzarini et al., 1996a,b; Egron et al., 1998): pathway 1, the compound first releases p-bromophenol then undergoes demethylation; and pathway 2, the compound first undergoes demethylation and then releases p-bromophenol. In stampidine-treated animals, we detected trace amount of p-bromophenol, the precursor of p-Br-Ph-S, but we did not detect the de-bromophenol product 2',3'-didehydro-3'-deoxythymidine 5'-(methoxyalaninyl phosphate, which is fairly stable in the plasma with a decomposition half-life of ~2 h. These results indicate that p-bromophenol is not released from the parent stampidine, otherwise we would have detected de-bromophenyl stampidine.

The metabolism of stampidine may involve demethylation first followed by the release of p-bromophenol, a theory consistent with recent reports of other STV aryl phosphoramide derivatives using an in vitro system by Saboulard's group (Saboulard et al., 1999; Siddiqui et al., 1999). Demethylated stampidine (Fig. 1) was, however, very difficult to synthesize; several attempts were made to cleave the methyl ester of stampidine, but in all cases either no reaction occurred or unwanted side reactions were observed. An analog of stampidine with a tert-butyl ester on the alanine residue was synthesized and subjected to a variety of mildly acidic conditions expected to provide the carboxylic acid. Every attempt to remove the tert-butyl group resulted in loss of bromophenol. Stampidine did not readily lose the bromophenyl group under these conditions. It is possible that de-bromophenyl stampidine was formed but was subsequently metabolized rapidly so that it cannot be observed experimentally. This was further supported by the hydrolysis of stampidine using the pig liver esterase because we observe Ala-STV-MP, STV and p-bromophenol, but no other significant peaks.

It has been established that the metabolism of aryl phosphoramides or nucleotides may be mediated by carboxyesterases, phosphodiesterase, ribonucleoside phosphramidase (Egron et al., 1998; McGuigan et al., 1998; Naesens et al., 1998). Our results showed that the cytochrome P450 system is not significantly involved in the metabolism of stampidine. The formation of p-Br-Ph-S must be catalyzed by sulfotransferase, which transfers a sulfuryl group from 3'-phosphoadenosine 5'-phosphosulfate to hydroxy or amino groups (Duffel et al., 2001; Negishi et al., 2001). The positive results after incubation of p-bromophenol with human liver cytosol in the presence of PAPS further support this hypothesis. Our results also showed that PLE is not involved in the sulfonation of p-bromophenol to form p-Br-Ph-S. In the presence of PAPS, formation of p-Br-Ph-S was significantly slower with the combination of both PLE and liver cytosol versus cytosol alone. This may be caused by the higher concentrations of Ala-STV-MP and p-bromophenol but less stampidine in the reaction system, However, the possibility that hydrolyzed products may inhibit the sulfonation reaction requires further study.

Sulfotransferases have been shown to be present in almost all animal species, including mice, rats, and dogs and also in human beings, but it should be noted that sulfotransferases are found to be genetically polymorphic in humans (Coughtrie et al., 1999; Nagata and Yamazoe, 2000; Evans and Ingelman-Sundberg, 2001). In addition, the level of available 3'-phosphoadenosine 5'-phosphosulfate in plasma, which has been found to affect acetaminophen sulfonation (Falany, 1997), may also influence the stampidine sulfonation. Therefore, there may be some variation in the further metabolism of p-bromophenol released from stampidine. There is no significant difference in metabolite pharmacokinetics (C_max, T_max, and t_1/2) of p-Br-Ph-S in mice after intravenously and orally administered stampidine, except for significantly higher systemic exposure (AUC) of p-Br-Ph-S after oral administration of stampidine compared with intravenous injection. Cats treated p.o. with 100 mg/kg stampidine have the highest plasma concentrations of p-Br-Ph-S and AUC, whereas there are similar elimination half-lives of p-Br-Ph-S in mice, dogs, and cats. The relative contributions of intestinal wall metabolism versus liver first-pass metabolism to the observed metabolism of stampidine after oral administration will be the subject of future studies.

Notably, stampidine inhibits the replication of primary clinical HIV-1 isolates with subnanomolar to nanomolar IC₅₀ values (Uckun et al., 2002c). Our results provided direct evidence that plasma concentrations of stampidine >4 logs higher than its IC₅₀ value can be achieved in both dogs and cats after its p.o administration at a 100-mg/kg dose level. In dogs as well as cats, stampidine was metabolized to yield the active metabolites ala-STV-MP and STV, which is similar to the pharmacokinetic profiles of stampidine in mice. The pharmacokinetics and metabolism profiles, and potent anti-HIV activity of stampidine warrant the further development of this new antiviral agent for possible clinical use in HIV patients.